MN-18

MN-18
Systematic (IUPAC) name
	N-(naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide
Clinical data
Legal status	CA: Schedule II;
Identifiers
CAS Number	1391484-80-2
ChemSpider	29763729
Chemical data
Formula	C23H23N3O
Molecular mass	357.5 g/mol
	SMILES CCCCCn1nc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2 ;
	InChI InChI=1S/C23H23N3O/c1-2-3-8-16-26-21-15-7-6-13-19(21)22(25-26)23(27)24-20-14-9-11-17-10-4-5-12-18(17)20/h4-7,9-15H,2-3,8,16H2,1H3,(H,24,27) ; Key:UJKHLVOEXULDRU-UHFFFAOYSA-N ;

MN 18 is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug.^[1]^[2] It is the indazole core analogue of NNE1. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of MN-18 may release 1-naphthylamine, a known carcinogen.

Legal status

MN-18 is banned in Sweden.^[3]

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.